Close

Synthon opens new GMP antibody-drug conjugate production facility in Nijmegen

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Revolutionizing Pharma Manufacturing with Biofermentation

Synthetic Chemistry and Integrated Biofermentation Transformational Pharmaceutical Manufacturing Combining biofermentation...

Thermo Fisher Launches Adolescent Alopecia Areata Registry

Thermo Fisher Scientific Inc., the global leader in serving...

Synthon Biopharmaceuticals has opened a GMP antibody-drug conjugate (ADC) production facility in Nijmegen.

The Nijmegen facility will produce ADCs, which combine specific anti-cancer antibody or antibody fragment to an anti-cancer therapeutic, required for Phase III trials and early launches.

Company has also reported positive preclinical results with its HER2-ADC that induced complete tumor remission when dosed alone in xenograft studies.

Toxicity experiments demonstrated improved therapeutic index and a considerable safety profile of HER2-ADC.

Synthon Biopharmaceuticals chief scientific officer Dr. Marco Timmers said the HER2-binding antibody trastuzumab is incorporated into the company’s first ADC program.

“The primary objective is to develop a broad therapeutic spectrum by targeting tumors that over-express HER2, such as metastatic breast cancer and non-small-cell lung cancer,” Dr. Timmers added.

“As a result of our unique linker-drug technology, this ADC program is delivering on its promise and giving us exciting preclinical results with the opportunity to become a Best-in-Class therapy.”

The drug candidate that will be produced in the newly opened GMP facility is expected to enter into clinical trials in 2014.

Latest stories

Related stories

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Revolutionizing Pharma Manufacturing with Biofermentation

Synthetic Chemistry and Integrated Biofermentation Transformational Pharmaceutical Manufacturing Combining biofermentation...

Thermo Fisher Launches Adolescent Alopecia Areata Registry

Thermo Fisher Scientific Inc., the global leader in serving...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back